Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an announcement.
On July 23, 2025, Oncolytics Biotech Inc. hosted a key opinion leader webinar to discuss the promising clinical data of pelareorep in treating pancreatic and gastrointestinal cancers. The event highlighted pelareorep’s potential as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), a condition with significant unmet medical needs. The webinar underscored the drug’s mechanism of action and its ability to enhance the immune response against tumors, positioning pelareorep as a valuable asset for pharmaceutical partnerships aiming to innovate in gastrointestinal oncology.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is dedicated to advancing cancer treatments, particularly in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. Oncolytics is actively conducting and planning combination clinical trials with pelareorep in solid malignancies to enhance its therapeutic potential.
Average Trading Volume: 210,535
Technical Sentiment Signal: Buy
Current Market Cap: C$161.3M
For detailed information about ONC stock, go to TipRanks’ Stock Analysis page.